Gastric cancer characteristics and care patterns in Algeria
Official title: Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria
Run by Société Algérienne de Formation et Recherche en Oncologie · NCT07481110 · Data updated 2026-11-12
This project collects medical records and short interviews to describe who has gastric cancer and how they are diagnosed and treated at Algerian oncology centers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Société Algérienne de Formation et Recherche en Oncologie Academic / other |
| Locations | 15 sites (Algiers, Algeria and 14 other locations) |
| Status | Recruiting |
| Started | August 5, 2025 |
| Main results expected | August 5, 2026 |
| Study ends | August 5, 2026 |
| Registry record updated | March 27, 2026 |
| Trial ID | NCT07481110 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 19 or older with a histologically confirmed gastric carcinoma who are followed at one of the participating Algerian oncology departments and can give informed consent.
✕Probably not a fit
Patients with non-carcinoma stomach tumors (for example GIST, lymphoma, or sarcoma), secondary gastric tumors, those under 19, or people enrolled in interventional studies are unlikely to benefit from this observational project's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a non-interventional, descriptive, cross-sectional study using both retrospective and prospective data collection. It seeks to characterize the demographic, epidemiological, clinical, diagnostic, and therapeutic features of about 1,000 patients with histologically confirmed gastric carcinoma in Algeria. Data come from hospital medical records and brief (≈30-minute) patient interviews, with all information anonymized for research use. No experimental treatments are given; the study documents current diagnostic and management practices at participating oncology departments.
Why it matters
Potential benefit: If successful, the results could help clinicians in Algeria detect gastric cancer earlier and make better-informed treatment decisions for patients.
How similar studies have gone: Similar national and international observational registries have successfully clarified patterns of gastric cancer and informed care, though Algeria-specific data have been limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 19 years and older * Histologically confirmed diagnosis of gastric cancer * Patients followed in the participating oncology departments * Informed consent obtained Non Inclusion Criteria: * Histological types other than carcinoma (e.g., GIST, lymphoma, sarcoma, etc.). * Secondary gastric tumors * Participation in an interventional study
Where it's running
-
CHU Béni Messous
Algiers, Algeria, Algeria Recruiting -
Cac Blida
Algiers, Algeria, Algeria Not yet recruiting -
Cpmc
Algiers, Algeria Not yet recruiting -
EPH Rouiba
Algiers, Algeria Not yet recruiting -
CHU Annaba
Annaba, Algeria Not yet recruiting -
CHU Constantine
Constantine, Algeria Not yet recruiting
Show 9 more locations
-
EPH Constantine
Constantine, Algeria Not yet recruiting -
CAC Oued Souf
El Oued, Algeria Not yet recruiting -
CAC Oran
Oran, Algeria Not yet recruiting -
CHU Oran
Oran, Algeria Not yet recruiting -
EHU Oran
Oran, Algeria Not yet recruiting -
CAC Sétif
Sétif, Algeria Not yet recruiting -
CAC Sidi Bel Abbès
Sidi Bel Abbes, Algeria Not yet recruiting -
EPH Sidi Ghiles
Tipasa, Algeria Not yet recruiting -
Cac Dbk
Tizi Ouzou, Algeria Not yet recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BHB810 in advanced gastric and GEJ cancer (early-phase)
This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.